We exam ined the space and temporal distribution s ofthe rotat ory evo ked brain elect rical acti vity patterns (b rain elec trica l acti vity ma pping of ves tibular evoked potentials (Vest EP}) in humans. We p erform ed a lon gitudinal scalp lin e ana lysis, tran sversal lin e analys is, and clockwise/counterclock wise rotati on analys is of the VestEP princip al co mpo nents in 75 healthy pers ons aged 22 to 30 years (me an: 25.8). We fo und that the sho rtest Ves tEP lat encies and the high est amplitudes were register ed in a rela ti vely di stin ct co rtica l ar ea that is covered by the tran sversal electro de lin e T3-C3-Cz.-C4-T4, in accordan ce wi th the 10120 int ernational electrode scheme . Thi s area co rrespo nds to the posteri or pa rt ofthe frontal lob e (Brodina nn 's area 4, the primary motor fi eld of the isocortex ) and the anterior parts ofthe cerebral pa rietal lob e (th e gy rus postcentralis, whi ch co rrespo nds to the primary so matosenso ry fi elds, Brodmann 's a reas I , 2, and 3). In thi s art icle, we di scu ss a method of investigation that exhibits the VestEPs, and we review one no rmal case and three typ ical cases ofpath ologi c Ves tE Ps.
Introduction
The ex iste nce of cortic al repr esentati on areas for vestibular efferents has been sugges ted by man y authors.1·-/Th ese functional (nonmorphologi c) observations are based principally on two app roache s: evo ked potenti al study foll owing stimulation of the lab yrinth in animal models' : and dir ect stimulation of the ex posed cort ex in hum ans; wh ich e licits a se nsation of vertigo and di zziness. In ca ts, the are a of maxim al activatio n dur ing an evo ked potenti al study was fo und to be located bilat erall y within the anterior sy lvian sulcus betw een the facial somatose nsory area and the auditory cortex .1.2 An ove rla p of the ves tibular repr esent ation existed with the so matose nsory zo nes . Fredri ckson et al reported that the primary cortic al vestibular proj ecti on s in rhesus monk eys were located in the postcentral gy rus at the lower end of the intrapari etal sulcus.' Thi s location cor res po nds to Brodmann ' s area 2. 6 The vestibular sensory area in human s has been thou ght to be located in the anterior portion of the parietal sulcus (Brodmann's area 2) . Moreo ver, so me part s of the somatosen sor y repre sentation of the upp er limb s appear to participate in the integration of the ves tibular and proprioceptive signals."
The purp ose of our study was to e va luate the cortic al distribution of ves tibular evo ked potenti als (VestEP) el icited by short-duration angular acce lerations in hum ans . Our analysis of the latency and amplitude paramet ers of the VestEP princ ipal component s, registered by multichannel electroencephalographic (EEG) recordings, served as the basis for a dete rmin ation of the corti cal focu s of maxim al VestEP acti vity.
Methods, materials, and subjects
Properties ofvestibularstimulation. Th e vestibulars timuli applied in this study were repetitive sho rt-duratio n rotatory mo vem ent s (stepwise angular acce lerations, clockwise [CW] and co unterclockwise [CCW] in consecut ive trials) of the subj ect's entire body around a vertica l axis. The on set of the positi ve acc eleration served as a trigger impul se fo r ave ragi ng the EEG seg ments. To prevent emotional stress and muscle artifacts, we used a slow SCHNEIDER. SCHNEI DER. C LAUSS EN, KO LC HEV Angular pe ak veloci t y [a/sec] Figure I . Scheme ofthe stimulus profile shows that Th e duration oj The acceleration and deceleration phases lI'as 1.000 tnsec each . deceleration (i.e., not a sudden stop). The rotational motion thus consisted of trials of CW and CCW constantacceleration impul ses. The interstimulus interval was 14.0 seco nds. and the duration of thc acceleration and deceleration phases was 1.000 msec each (figure I).
After prelimin ary investigations, we chose an angular acceleration and deceleration intensity of ISo/sec". In this way, the angular velocity rose from OO/sec to a maxi mum peak velocity of ISo/sec. The common step amplitude for both the positive and negative acce leration phases was 30°.
In all, we averaged 25 stepwise rotations for eac h of the CW and CCW rotations. To avoid the possibility of habituation in any patient, we scheduled a lapse of 3 to 5 minutes between consecutive sess ions. The average duration of each sessio n was approximately 30 minutes, including the time necessary to mount the electrodes, Equipment. We used a direct-drive servocontrolled ServoMed AB Rotation Chair RS/6, which had an option for 17 self-contained, self-supplied direct-current (DC) preamplifi er s (input res istance: 400 MOhm s). Th e biosignals were transmitted to the main amplifier through a slip-ring assembly ; the assembly co ntained 17 slip rings, and each was equipped with twin sliding co ntacts. Digital setting and monitoring of the angular speed and acce leration were also available. The stimulus profile was programmed by a function generator. While in operatio n, the rotating chair was co mpletely silent. Even so, we applied individual hearing protectors to both ears of each subjec t in order to avoid a possible acoustic contribution to the rotationally evoked potentials.
Each patient was positioned in the chair with his or her head inclined forward by 30°. To minimi ze eye-movement artifacts, we used a gaze-fixation target that rotated
Results
Lat ency properties and scalp distribution ofthe VestEP components. The VestEP waveformselicited by the abovedescribed procedur es consisted of six positive (P) or negative (N) wave comp onents, which appeared within intervals of 50 to 850 msec after the onset of the acceleration sti mulus (table I) . The most prom inent part of the compound VestE P co mplex was the III-IV-V wave segment.
The respo nse was nearly always well structured during the first few applicat ions of the stimuli. Both the CW and CC W acce lerations basically elicited similar wave pattern s, although some differences or peculi arit ies do exist among clinically health y persons. Sometimes an interme-with the chair. The chair was housed in a semilighted room, which allowed us to examine each patient either in total darkness or in an illuminated environment. Eye movement s wcre monitored on a spec ial electrooculographic channel.
A set of Ag/AgCI-sintcred electrodes was placed over the scalp according to the internationally used 10/20 system. We used severa l montage schemes and programs, some of which included the middle line electrodes Fz and Cz. Altoget her. we used 19 scalp electrodes to study the scalp topography of the VcstE P. The amplification and paper monitoring of the raw EEG data were performed by a 17-channel Picker Schwarzer Encephaloscript ES 16000 (input impedance: 100 MOhms).
The reference electrode was fixed to a line connecting both mastoids at the rear center of the skull. Upward deflections indicated scalp negativity. The frequency band of the recorded spo ntaneous brain electrical activity was determined by a low-frequency cutoff of 0.1 Hz and a high-frequency cutoff of 35 Hz. A 50-Hz notch filter was applied. The responses were monit ored online and subsequently processed on a Schwa rzer Brain Surveyor BS 2400, which supplied facilit ies for spatial and chronologie analysis of both spontaneous and evoked brain electrical acti vity (brain electrical activity mappi ng lBE AMj).KFollow ing the onset of the stepwise acceleration stimulus. a period of 1.000 rnsec was used for analysis of the rotatory evoked brain electrical eve nts. Peak-topeak ampl itudes and princ ipal component latencies were measured and subsequently co mputed on a personal co mputer for their mean values and standard dev iations.
Subjects. The reference data were obtained from 75 healthy volunteers (mostly medical stude nts) who had no diagnosed neuro logic or ncurotologic disorders. The 40 men and 35 women were aged 22 to 30 years (mean: 25.8).
In addition. we also investigated a few children (age: 9 to I I yr) and a few older persons (age : 37 to 55 yr) to appreciate the age-related variability in the VestEP propert ies. The addition of these subjects raised the mean age of the entire group to 30. 1 years. The frequency andmagnitude01laboratory abnormalities weresimilar in lexofenadinehydrochlorideand placebo-treated patients. Pediatric. Table 2 lists adverse expe riencesin patients age d 6 to 11 years of agewhichwerereported bygreater than2% 01pat ientstreated with texclenadine hydrochloride tabletsat a dose of 30 mg twice daily in placebo-controlled seasonal anergic rhinitis studies in the United States andCanada that were more common with fexotenadine hydrochloridethan placebo. Hemodi alysis did noteffectivelyremovefexotenadin e hydrochloride fromblood (1.7% remo ved)followingtertenadine administrati on. Nodeaths occurred at oral dosesof fexofenadine hydrochloride upto 5000 mglkgin mice(110times the maximum recommended daily oral dosein adult s and200timesthe maximum recommended dail y oral dose in childrenbas edon mg/m l ) and up to 5000mglkg in rats (230times themaximum recomm. ended daily oral dose in adu lts and400times themaximum recommended dally oral dose in children based on mg/m l ) . Add itionally, noclinical signsof toxicity or gross pathological fmdings wereobserved. In dogs , no evidence 01toxicity was observed at oral doses up to 2000 mglkg (300timesthe maximum recommended daily oral dose in adults and 530times the maximumrecommended dai ly oral dose in chil dren basedonmg/m 1 ) .
Chronic IdiQ palhjc Urticaria
Adverseevents reported bypatients 12years of ageandolder in placebo-controlledchronic idiopathic urticaria studies were similar to those reported in placebo-controlled seasonal allergic rhini tis studies. In placebo-controlled chronic idiopathic urticaria clinical trials. which included 726pat ients 12 years of ageandolderreceivinp fexofenadi ne hydrochloride tablets at doses of 20 to 240 mg twicedaily, adverse eve nts were similarin fexofenad inehydrochloride andplacebo-treated pat ients. Table 3 lists adverseexpe riences i.n patients age d 12years andolder which werereported bygreat er than 2% of patients trea tedwith fexofenadine hydrochloride 60 mg tablets twicedaily in controned clinicalstudies in theUnited Statesand. C a~a d a and that were more~o~~on~i t h f~x of~n ? · dinehydrochl oride than placebo. Thesafety of fexofenadine hydrochlorideIn thetreatment 01chronicidiopathic urticaria In pediatric pat ients 6 to 11 years of ageis based on thesafety profile of lexofenadine hydrochlori de in adults and adolescent patients at doses equal to or higherthan the recommended dose (see Pediatric Use). Table 3 Adverse expe riencesreported in patients 12years and older in placebo-controll ed chronic idiopathic urticaria studies in the United States and Canada at rates 01 greater than 2% Fexofenadine 60 mg twice dail y (n" 186)
Adverse experience elderly pat ientsarem~re likely to have decreased renal functi on. care should betaken in doseselection, andmaybeuseful to monitor rena l function. (See CLINICAL PHARMACOLOGY). ADV ERS EREACTIONS Seasonal Allergjc Rhinitis . . Adull s. In placebo-cont rolledseasonal allergic rhinitis clinical trialsin patients 12 years ot ageandolder, whichincluded 2461 pat ientsreceiving fexofenad inehydrochloridecapsu lesat doses of 20 mg to 240mg twicedaily, adverse events were similar in lexofenadine hydroch lorideandplacebo-treated pat ients. All adverse events that were reported by greate r than 1% of patients who receivedthe recommended dai ly doseof Iexotenadme hydrochloride(60 mgcapsu lestwice dai ly),and thatwere more common with Iexofe nadine hydrochlori de than placebo, arelisted in Table 1. In aplacebo-controlledclinical studyin theUnited States, whichi n~luded 570 pat ients aged .12.ye~rs andolder.recei vingtexctenadtne hydrochloride tablets at dosesof 120 or 180 mgonce dally , adverse events wereSimilar In Iexclenadine hydro~hlo rideand placebo-treated patients. Table 1 also lists adverseexperiences t h a~were reported by greater than 2~o of patients treated with lexofenadine hydrochloride tablets at doses of 180 mg once dally and thatwere morecommon W ith texofenadine hydrochloride than placebo.
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coJIegmf exofenadine HCI
• Nonsedating eve n a t more than twice the reco mmende d 18 0 mg qd dose" fllilnill<Y Ter atogenic Elfecls: Category C. Therewasno evidenceof teratogenicity in rats or rabbits at oral doses of terfenadineup to 300mglkg(which led to fexctenadine exposures thatwereapproximately 4 and31 times, respectively, theexposurefrom the maximumrecommended daily oraldose of fexofenadine in adults). There arenoadequateand well cont rolled studiesin pregnant women . Fexofenadine shoul d be used duri ng pregnancy onl y jf the potential benef it justif iesthepotential riskto thefetus . Nont eratogeni c Effects. Dose-related decreases in pupweight gain andsurvival were observedin rats exposed to anoraldose of 150mglkgof terfenadine(approximately 3 timesthe maximumrecommended dail y oral dose of fexofenadine hydrochloridein adults based oncomparisonof fexofenadine hydrochloride AUCs).
Nursing Molhers
There are no adequateandwell-controlled studies in women during lactation. Because many drugsare excreted in human milk. caution should beexer cised when fexofenadinehydrochlorideis administered to a nursing woman.
The recommended dose in patients 6 to 11 years of ageis based on cross-study comparison 01the pharmacokinetics of ALLEG RAin adultsandped iatricpatientsandon thesafety profileol fexcfenadine hydrochloride in bothadult andpediatric patients at dosesequal to or higher thanthe recommended doses.
The safety of ALLEG RAtabletsat a dose of 30 mgtwice daily hasbeen demonstrated in 438pediatric patients 6 to 11 years of agein two placebo-controlled 2-week seasonal allergic rhinitistrials. The safetyof ALLEGRA for thetreatment 01chronic idiopathic urtica riain patients6 to 11years of ageis based on cross-study comparisonof thepharmacokinetics of ALLEGRA in adultandpediatric patients andon the safety profile of fexofenadinein bothadult andpediatri c patients at dosesequal to or higherthan therecommended dose. The effectiveness 01ALLEGRA lor the trea tment of seasonal allergic rhini tis in patients 6 to 11 years of agewasdemonstrated in onetrial (n=411) in which ALLEGRA tablets 30 mgtwice dail y significan tly reducedtotal symptom scor escomparedto placebo, along withext rapo lation 01demonstrated efficacy in patients ages 12 years andabove, andthe otarmacoklnetlc comparisons in adults andchi ldren. The effectiveness 01ALLEGRA for the treatment of chronic idiopathic urticariain pat ients 6 to 11years of age is based onan extrapolationof the demonstrated efficacy of ALLEGRA in adults with thiscondition and the likelihood that the disease course, pathophysiology andthe drug's effect aresubstantiall y simila r in children to that of adult pat ients. The safety andeffectiveness of ALLEGRA in pediatric pat ients under 6 years of agehave not been established .
Clinicalstudies 01ALLEGRA tabletsandcapsules did not include sufficient numbers of subjects aged 65 years andover to determinewhether this populati on responds differentl y from younger patients. Other reported clinical experience has not identifieddifferences in responses between the geriatric andyounger patients. Thi s drugis known to besubst antiallyexcretedby thekidney,andtherlsk 01toxic reactions to this drugmay begreater in patientswith impaired renalfunction . Because *Adm inistered as 240 mg bid for 14 da ys (n= 144). There is no evidenc e that doses higher than those recommended ore more effective . Furt hermore, there was also a direction-depende nt (labyrinth-re lated) difference in the VestEP components' latencies. Thu s, the VestEP laten -Component cies produced by a rotation directed to the left denomination (CCW stim ulus) appeared to be slightly sho rter , at least for some of the electrode derivations, than the corresponding VestEP latencies that were elicited when rotating toward the right in the CW stimulus (labyri nth-related analysis). These CW/ CCW latency differences we re statistica lly significant for the 1st component registered from the T5, P3, and P4 der ivations, for the IVth component registered from the F8, T3, Cz, T4, P3, T6 , 0 1, and 02 derivations , and for the Vth component reg istered from the P3, P4, T6, 0 I, and 02 derivations .
Th e presence of some degree of interhemispheric asymmetry in Ves tEP component latencies (transversal line ana lys is) was also notable. In ge neral, the latency differences between the left and right hemispheres were not significant. The only exceptions were the T5-T6 and P3-P4 derivations, in whic h the latencies obtained from the left hemisphere were significantly shorter than those obtained from the right Amplitude mapping of the VestEP. The amp litude mapping of the Ves tEP was performed with respec t to the IIIrd and IVth peak-to-peak segments. The highest VestEP ampli tudes were registered at the Cz, C4 , F4, and C3 cortical areas . At the areas more fro ntal and more occ ipital from the transversal line (the T3-C3 -Cz-C4-T4 line), the response was progressive ly less in its ampli tude . The lowest amp litudes were registered in the occip ital and fron tal areas . Th e differences with respect to the response obtained from Cz (CW rotation) were highly significa nt: Fpl, Fp2 , F7, T3, T5, T6, P3, 01, and 02 (p::O;O.OOI). diate peak was de tected in the initia l wave complex (between the 1st and lI nd or lIn d and IIIrd wave segments). T he response curves show a relative ly low to modera tely stressed varia bility intra-and interindividually.
The nomenclature of the VestEP components was established in terms of the negative peaks (the only exception being the IVth compone nt, which was the most dominant and stable positive peak). Thus, the peaks ' nomencla ture according to their average latency was N75 (N-I) , N I80 (N-II), N330 (N-III) , P480 (P-IV), N630 (N-V), and N800 (N-VI); these values were averaged from the CW and CCW stimuli (table I) .
The sca lp place ment of the electrodes significantly influences VestEP com ponent latencies. The shortest latencies of the initial VestEP components (Is t, lI nd, and IIIrd) were obtai ned from the central transversal line area (the T3-C3 -Cz-C4 -T4 electrodes). The shortest latencies of the later components (IVth, Vth , and Vl th) were registere d from the more frontally located brain regions (Fp I, Fp2, and Fz) .
Our statistical analysis according to the Student's t test revealed that there were significant differences in latency among the various VestEP components, dependi ng on the electrode's location on the anteroposterior plane (Iongit udina l line analysis). Th e VestEP latencies of the 1st and lInd components registered from the Cz electrode (CW rotation) were significantly shorter than those from the P4, T6, 0 I, and 02 derivations. The latency differences for the IIIrd and IVth Ves tEP components were even more wide ly expressed: F8, T6, and 02 ( right facial palsy and encephalitis herp eti ca , whic h led to the progressiv e and se vere hearing and ves tibular loss o n the righ t. In 1992 , he was diagnosed with type 2 diabetes mellitu s and seconda ry polyneur opath y. In 1994 , he underwent a retrom asto id cra niec tomy with an ex tended cyst resec tio n o n the left.
Priorto 1995, the man had undergone brai nstem evoked respo nse audiometry (BERA), computed to mog raphy (CT) , and a ne uro log ic exa mination. T he BER A revealed no potent ials on the left and a patho logic mor phology of the cur ves and a prolon ged interp eak latency of the IIII' d, IVth , and Vth wa ves on the right. CT demon stra ted large alterations of the le ft mastoid, petro us, and tem poral bones (bone proli feration , fibros is. chro nic infla mmation , and cicatriza tio n), a slight co mpres sion of the le ft cerebellar hemi sph ere, and a non specific e nhance ment of the right labyrinth ( figure 3) . Th e neur ologic ex amination de tect ed anac usis on the left , seve re hypoacusis on the right , a co mplete vestibul ar loss bilaterall y, a very slight paresis of the right facial ner ve, and no signs of co mpression of the ce rebra l structures. 256 We per form ed our own co mplete neurotolo gic inve stiga tion, which included e lectronystag mography (ENG) and cra niocorpog ra phy (CCG) . Th e ENG revealed normal op tokinetics, a co mplete ca lor ic arefl exia on the right , an imp ossible left cal orizati on on the left (w hic h was ca used by the obstruction of the ex ternal aud itor y can al by bone pro liferation), and no response to rot atory tes ting. T he CCG revealed ext reme ataxia; the patient wa s not ab le to take more than 30 steps during Unterberger' s test (norma l: 100) or to rem ain stand ing for mo re than 27 seconds du ring Romberg' s test (norma l: 60 ).
We used the BEAM-VestEP investi gation to confirm the presumed diagnosis of a co mplete bilatera l vestibular loss. On BEAM-Ve stEP , no co rtica l response/potential to the vestibular stimulatio n could be recorded because of a co mplete bilater al destru cti on of the lab yrinth rece ptors (fig ure 3) .
We found it extre me ly interestin g to observe how this patient was able to use his visual and propri ocept ive functions to co mpe nsa te for his complete lack of ves tibular funct ion and his very severe loss of auditory fun ction . · Introducing a revolutionary surgical mesh for tissue reinforcement. .
SURGISIS' " Soft Tissue
Graft is a surgical mesh for tissue reinforcem ent. While SURGISIS reinforces and suppo rts th e surgical site, the body's natural healing process can repair weak tissue. Over tim e, SURGISIS is repl aced by natural host tissue. Versatile for many applications. SURGISIS is available in a variety of sizes and strengths and can be cut, roll ed or fold ed . Thin and pliabl e, SURGISIS is stro ng enough to be su tured or stapled . Incorporates SIS technology. SURGISIS is mad e from Small In testinal Submucosa (SIS), a naturallyoccurring extracellular matrix. Th e matrix, when surgically implanted, provides str ength to reinforce weakened tissue. (No adverse immunological response or sen sitization to SIS has been documented.) Delivered with COOK's 'outstandingcustomer service. SURGISIS is one of th e new SIS technology products from COOK, a name synonymous with gr eat medic al innovation and ou tstan ding customer service. To learn more about SURGISIS and the othe r SIS products, contac t your COOK sale s representative . Call toll fre e 1-800-457-4500 or visit us on the Web at www.cooksis.com. Th e man was able to lead a relat ive ly normal life and enjoy a satisfacto ry degree of social independe nce .
SURGISIST \f A Reooluiionars New Technology
Patient 3: Acoustic neuroma. A SS-year-old-man came to our facility with a 10-year histor y of tinnitus and a progressive hear in g loss in the sa me ear. He had no subjective co mplai nts of vertigo and no bal ance dis turba nce s.
We performed a ro utine neurotol ogi c exam ination (figure 4) . Caloric testi ng showed a partial inh ibition (cold water) on the left and disin hibitio n on the right. The rotatory inte nsi ty da mpi ng tes t showed recruitment on the le ft side, and the CCG showed a peripheral ves tib ular di sturbance with an ang ular deviati on to the left. Th e BER A was normal (fa lse negati ve), and a pure-ton e 258 audiogram showed a slig ht middle -and high-frequ en cy hear ing loss on the left.
Th e BEAM-Ves tE P in vesti gation showed an amplitud e reducti on of the VestEP (C 4 deri vation ) and a laten cy delay of the ea rly compon ent s during rotati on to the affected left side (fig ure 4) . Th e man was di agn osed with an in tra meata l sc hwanno ma of the VIIIth nerve on the left side. Patient 4: Tinnitus. A 62-year-old man re ported that he had been suffering from a severe and dis abling bilateral tin nitus for the pre vious 8 years . A pure-to ne audiogram showed a moderate high-ton e slope . T he pati ent describe d his tinni tus as a loud murmur, and he sa id that a side local ization was no lon ger possibl e. Th e no ise co uld not be masked. Th e man had no other neu rot ol ogi c co mplaints. We performed a VestEP in vesti gati on .
Accordi ng to previou s studies publis hed by member s of our working gro up, patients with tinnitu s ex hibit three primary find ings on VestEP: a shor tening of the Ves tE P latencies, an increased am plitude of the III rd and IVth peak-to-peak component, and a DC shift of all Ve stE P co m po nents toward the negative pol e." !' Ind eed , that is j us t w hat we found in thi s pa tient (ta ble 2) . Th ere was a shor te ning of the laten ci es (es pec ially the lat e waves) during rotatio n to the right. In addition, ther e was a slight DC shift of the curve toward negat ivity. During the left rota tio n, the shortening of the laten cies was less clearly defined, but there wa s a clear shift of the curve toward negati vity, es pecially in the late waves ( figure 5 ) .
Discussion
Our st udy revealed that rotatory evoked brain elec trical events are broadly di stributed over the human co rtex. However, the sho rtes t Ves tE P laten cies and the high est amp litudes are registere d in the relati vely distinct corti cal area that is covered by the transver sal elec trode lin e T 3-C3-Cz-C4-T4 accordi ng to the 10120 internat ion al sc he me of electrode placement." T his line is a tra nsverse strip be tween the midtemporal electrodes and the ve rtex point (Cz electrode).
Long itudinal line an alysi s of the principal Ve stE P compo ne nts ind icated that statistically significant differen ces existed only be tween the ce ntro parietal and fro nto po lar area s an d bet ween the ce ntroparietal and occipito po lar areas . Thi s indi cates tha t a rel ati vel y wide cortical regi on , co ve red by the central and pari et al EEG elec tro de s, has prevai ling functiona l co nnec tions with the vestib ular nucle i and subcortical ves tibu lar pat hways. T his area corresponds to the posterior part ofthe fronta l lobe (Brodrnann' s area 4 , the primary motor field of the isocortex) and the anterior part s of the ce rebral pa rietal lobe (the gyrus postce ntral is, w hic h corresponds to the pr imary somatosensory fie lds, B rodm anri' s areas 1,2, and 3) .6.12.15O ur opi nio n is that this area corresponds to the prim ar y ves tibul ar cortex.
Scaling New Heights In Medical Solutions
For more information Circle 113 on Reader Service Card oal t a r~ur M,di(i SOFTWARE Mountainside" Software has developed a complete software solution for today's medical practice. Each system works independently or seamlessly interfaces to help your practice improve both patient care and profitability, streamline financial management and eliminate paper files .
The Allergy Lab System can automate the time consuming processes that affect the smooth operation of your practice.
The Mountainside Practice Management System can streamline and simplify the financial management of your practice, automatically.
The Electronic Medical Records System can eliminate paper files and charts from your practice while protecting the security and confidentiality of stored information.
To increase the productivity and profitability of your allergy practice, depend on the innovative solutions from Mountainside" Software. Call 800-851-0847 today for a free Demo CD.
For more information, visit our websites: Ma ny authors agree that no we ll-defined cortica l area exis ts for the tra nsfer of ves tibular information .l-" :" As is evi de nt from our data, the ves tibular induced afferents did essentia lly modi fy the electrical activ ity of the primary somatosensory cortex, whic h wou ld ind icate th at in so me aspects the ves tibular source is a type of somatose nsory sensation. T he BEAM-Ves tE P met hod is currently unable to different iate among the semicircular, otolithic, and pro prioceptive co ntri bu tio ns in the co mplex ves tibular affere nt impulse. However , physiologically it is also not probable that complex bod y and head movem ent s are ind ividually stim ulating eac h of those senses ind ependently.
Dur ing the rotatory stimulus (angular acce lera tion steps) that we used in this study, some other non vestibular sensa tions were also apparent-for example, delicate vibrations of the turn tabl e and air movem en ts aro und the face and body. Con sid er ing this finding, we beli eve that a VestEP event rep resent s an elici tation of a co mpo und brain electrical evoked potent ial by a ves tibular stim ulus, 110 77 ± 10
The methodology that we used to reac h this conclus ion oug ht be co nsidere d. Th e BEAM-VestEP app roac h is a new ly developed tec hno logy for con ducting functional brai n investigations in vivo . Ques -Stimulus tions regar ding the nature of the VestE Ps, the sites where they are ge nera ted , and the clinical value of these potentials have ROTR been add ressed in our previous ly published papers . 9 . 11. 1 6-~5
Based on the latency values of the Normal principa l Ves tE P co mpo ne nts in our values study, we co nclude that the particular response registered by our experimen ta l paradigm was most likely ge nerated at cortical levelsthat is, in both the pri mari ly vestibular and in the nonspecific associative areas . Our multielectrode arra ngement had a special advantage in BEAM in that it allowed us to receive additiona l to podiagnostic synoptic information .
Our experience with brai n mapping studies of the VestEP with a full set of 19 sca lp electrodes and a powerful co mp uter -assisted drawing techniqu e for processing data info rms us that the Ves tEP complex consists of two principa l p a rt s . l l . I S . 1 9.~J. 2~.~4 The firs t part co nsists of a relatively early set of components (Is t, lIn d, and IIIrd ), which mos t likely reflects the activ ation of the sensoryspecific cor tical areas . T he seco nd part is a re latively late one (IVth, Vth, and VIth) , whic h is as sociated with the more fron tally located scal p areas and thu s probably reflects the high level of supramodal processing wit h sensory informat ion.
In study ing evoked potentia ls, neurophysiology is being used to co nsi de r the area of shor tes t latencies and higher ampli tudes as a foc us of maxim al activity-that is, as a representat ive func tional area for the corresponding modality .~6 .7 Despite the fac t that the ge nerator site s and physiolog ic connotation s of the Ves tEP co mpo ne nts are stilI not firmly estab lis hed, important co nside rations are necessary rega rd ing the ves tibular nature of the Ves tEP events as registered in publ ished elec trop hysiologic studi e s . ' 1.~S -4 3 We have proven the met hod in health y control volunteers under various psychologic (en dogenic) and environmental (exogenic) co ndi tions, includ ing pharmacotherape utic stud ies. l l . 1 6 . 1 9 .~J.24 A4 Th e princi pa l Ves tE P parameters-such as the components ' latencies, am plitudes, and distributi on in space and time over the cor texrespond very se nsi tive ly and specifically relative to those modificatio ns in the intrin sic or extri nsic envi ronment. Furthermore, the numerous investigations of patien ts who had a var iety of neu rotologic sy ndromes have de monstrated the depth of information and the re lia bility of the VestEP a p proac h. 9-l l . 1 7 . I S . O . 22.~3 .~5 A special challenge now lies in the fie ld of tinnito logy, where we were able to demonstrate typical co rtica l hyperactivity ph enomen a.
CORTICA L REPRESENTATIO N O F THE VESTIBULAR SYS TEM AS EVIDENCED BY BRAI N ELECTRI CAL AC TIVITY MAPPING O F VESTIBULAR LATE EVO KED POTE NTIALS albe it one that co ntains so me somatosensory and, in particul ar, proprioceptive co ntrib utions. Howe ver, in cases of bilate ral loss of the inner ear recept ors, VestEP s ca nnot be elic ited.
We ca n now empirica lly differen tiate at least four ca tego ries ofVestEP res ponse , all of which we illustra ted in the case reports: statistica lly and clin icall y norm al res po nses (patient I), abse nt res ponses (patient 2), slow and pro longe d res po nses (pa tie nt 3), and overactive respo nses with shortened latencies (patient 4).
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